Do Specialized Cancer Centers Improve Outcomes for Patients With Ewing Sarcoma?
Patients with Ewing sarcoma aged 19 to 39 years may benefit from treatment at a specialized cancer center.
Diagnosis & Disease Information
Young Patients With CLL At Risk for Secondary Cancers
Patients with chronic lymphocytic leukemia younger than age 55 are at an increased risk for multiple types of secondary cancers for up to 15 years after diagnosis.
Ibrutinib Provides Long-term Benefits for Patients With CLL
Ibrutinib provides long term survival benefits to patients with chronic lymphocytic leukemia regardless of cytogenetic risk factors.
Durable PFS With Fludarabine, Rituximab, and Lenalidomide in CLL
Fludarabine and rituximab plus lenalidomide results in durable prolonged PFS compared with FR or FR plus cyclophosphamide among patients with untreated chronic lymphocytic leukemia.
Cediranib Prolongs Progression-free Survival in Alveolar Soft Part Sarcoma
Data suggest that cediranib-treatment of ASPS results in a substantial reduction in tumor burden and prolonged PFS.
Regorafenib Clinically Active in Ewing Sarcoma
SARC024 study met its primary endpoint for patients with Ewing sarcoma, and enrollment is ongoing for the liposarcoma and osteosarcoma cohorts.
Pazopanib Active in Malignant/Dedifferentiated SFT
Pazopanib showed antitumor efficacy among patients with unresectable or metastatic malignant/dedifferentiated soft fibrous tumors.
Affordable Care Act Increased Rate of Early Cancer Diagnoses
The US Affordable Care Act may have increased the proportion of patients with cancer diagnosed at stage I, according to a study.
Adjuvant Gefitinib Prolongs Disease-free Survival in Non-small Cell Lung Cancer
Adjuvant gefitinib significantly prolongs disease-free survival compared with vinorelbine plus cisplatin among patients with stage II to III non-small cell lung cancer.
- Loading...
Loading...
Next post in ASCO 2017
Loading... 
Loading...